Therapeutic Potential of Tumor Treating Fields for Malignant Brain Tumors

Overview

Journal Cancer Rep (Hoboken)

Specialty Oncology

Date 2023 Mar 29

PMID 36987739

Authors

Youyou Zhou

Xiaoqing Xing

Jinyun Zhou

Han Jiang

Peili Cen

Chentao Jin

Yan Zhong

Rui Zhou

Jing Wang

Mei Tian

Hong Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Malignant brain tumors are among the most threatening diseases of the central nervous system, and despite increasingly updated treatments, the prognosis has not been improved. Tumor treating fields (TTFields) are an emerging approach in cancer treatment using intermediate-frequency and low-intensity electric field and can lead to the development of novel therapeutic options.

Recent Findings: A series of biological processes induced by TTFields to exert anti-cancer effects have been identified. Recent studies have shown that TTFields can alter the bioelectrical state of macromolecules and organelles involved in cancer biology. Massive alterations in cancer cell proteomics and transcriptomics caused by TTFields were related to cell biological processes as well as multiple organelle structures and activities. This review addresses the mechanisms of TTFields and recent advances in the application of TTFields therapy in malignant brain tumors, especially in glioblastoma (GBM).

Conclusions: As a novel therapeutic strategy, TTFields have shown promising results in many clinical trials, especially in GBM, and continue to evolve. A growing number of patients with malignant brain tumors are being enrolled in ongoing clinical studies demonstrating that TTFields-based combination therapies can improve treatment outcomes.

Citing Articles

Integrating electromagnetic cancer stress with immunotherapy: a therapeutic paradigm.

Fuster M Front Oncol. 2024; 14:1417621.

PMID: 39165679 PMC: 11333800. DOI: 10.3389/fonc.2024.1417621.

Directionally non-rotating electric field therapy delivered through implanted electrodes as a glioblastoma treatment platform: A proof-of-principle study.

Ma J, Singh S, Li M, Seelig D, Molnar G, Wong E Neurooncol Adv. 2024; 6(1):vdae121.

PMID: 39156619 PMC: 11327618. DOI: 10.1093/noajnl/vdae121.

Enhancing glioblastoma treatment through the integration of tumor-treating fields.

Szklener K, Bilski M, Nieoczym K, Mandziuk D, Mandziuk S Front Oncol. 2023; 13:1274587.

PMID: 37916157 PMC: 10616854. DOI: 10.3389/fonc.2023.1274587.

Prospects of earthworm coelomic fluid as a potential therapeutic agent to treat cancer.

Haque S, Hussain A, Almalki A, Aldawsari M, Lal B, Rai A Cancer Metastasis Rev. 2023; 43(2):621-637.

PMID: 37910294 DOI: 10.1007/s10555-023-10148-5.

Therapeutic potential of tumor treating fields for malignant brain tumors.

Zhou Y, Xing X, Zhou J, Jiang H, Cen P, Jin C Cancer Rep (Hoboken). 2023; 6(5):e1813.

PMID: 36987739 PMC: 10172187. DOI: 10.1002/cnr2.1813.

References

Davis M . Epidemiology and Overview of Gliomas. Semin Oncol Nurs. 2018; 34(5):420-429. DOI: 10.1016/j.soncn.2018.10.001. View

Ceresoli G, Aerts J, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck J . Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019; 20(12):1702-1709. DOI: 10.1016/S1470-2045(19)30532-7. View

DeBerardinis R, Chandel N . We need to talk about the Warburg effect. Nat Metab. 2020; 2(2):127-129. DOI: 10.1038/s42255-020-0172-2. View

Tian M, He X, Jin C, He X, Wu S, Zhou R . Transpathology: molecular imaging-based pathology. Eur J Nucl Med Mol Imaging. 2021; 48(8):2338-2350. PMC: 8241651. DOI: 10.1007/s00259-021-05234-1. View

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent M . Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9(5):453-61. DOI: 10.1016/S1470-2045(08)70125-6. View

Barreca M, Stathis A, Barraja P, Bertoni F . An overview on anti-tubulin agents for the treatment of lymphoma patients. Pharmacol Ther. 2020; 211:107552. DOI: 10.1016/j.pharmthera.2020.107552. View

Tooley A, Gilden J, Jacobelli J, Beemiller P, Trimble W, Kinoshita M . Amoeboid T lymphocytes require the septin cytoskeleton for cortical integrity and persistent motility. Nat Cell Biol. 2008; 11(1):17-26. PMC: 3777658. DOI: 10.1038/ncb1808. View

Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View

Probst U, Fuhrmann I, Beyer L, Wiggermann P . Electrochemotherapy as a New Modality in Interventional Oncology: A Review. Technol Cancer Res Treat. 2018; 17:1533033818785329. PMC: 6048674. DOI: 10.1177/1533033818785329. View

10.

Toms S, Kim C, Nicholas G, Ram Z . Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2018; 141(2):467-473. PMC: 6342854. DOI: 10.1007/s11060-018-03057-z. View

11.

Li X, Yang F, Rubinsky B . A Theoretical Study on the Biophysical Mechanisms by Which Tumor Treating Fields Affect Tumor Cells During Mitosis. IEEE Trans Biomed Eng. 2020; 67(9):2594-2602. DOI: 10.1109/TBME.2020.2965883. View

12.

Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X . The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016; 18(8):1129-36. PMC: 4933490. DOI: 10.1093/neuonc/now102. View

13.

Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N . Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. Front Oncol. 2022; 12:896246. PMC: 9106370. DOI: 10.3389/fonc.2022.896246. View

14.

Salzberg M, Kirson E, Palti Y, Rochlitz C . A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie. 2008; 31(7):362-5. DOI: 10.1159/000137713. View

15.

Park J, Song K, Jung S, Ahn J, Hwang S, Kim J . Tumor-Treating Fields Induce RAW264.7 Macrophage Activation Via NK-κB/MAPK Signaling Pathways. Technol Cancer Res Treat. 2019; 18:1533033819868225. PMC: 6691660. DOI: 10.1177/1533033819868225. View

16.

Zhou Y, Xing X, Zhou J, Jiang H, Cen P, Jin C . Therapeutic potential of tumor treating fields for malignant brain tumors. Cancer Rep (Hoboken). 2023; 6(5):e1813. PMC: 10172187. DOI: 10.1002/cnr2.1813. View

17.

Wu H, Yang L, Liu H, Zhou D, Chen D, Zheng X . Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study. CNS Neurosci Ther. 2021; 27(12):1587-1604. PMC: 8611775. DOI: 10.1111/cns.13750. View

18.

Kirschenbaum D, Amit I . Brain metastases: Not all tumors are created equal. Neuron. 2022; 110(7):1097-1099. DOI: 10.1016/j.neuron.2022.03.027. View

19.

Akbarnejad Z, Eskandary H, Dini L, Vergallo C, Nematollahi-Mahani S, Farsinejad A . Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G). Biomed Pharmacother. 2017; 92:254-264. DOI: 10.1016/j.biopha.2017.05.050. View

20.

Zhao W, Steinfeld J, Liang F, Chen X, Maranon D, Ma C . BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature. 2017; 550(7676):360-365. PMC: 5800781. DOI: 10.1038/nature24060. View